scholarly journals Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer

2016 ◽  
Vol 7 (2) ◽  
pp. 114-126 ◽  
Author(s):  
Abena S. Agyeman ◽  
Wesley J. Jun ◽  
David A. Proia ◽  
Caroline R. Kim ◽  
Maxwell N. Skor ◽  
...  
2020 ◽  
Vol 31 (17) ◽  
pp. 1867-1878
Author(s):  
Hengyi Shao ◽  
Qingwei Zhu ◽  
Huasong Lu ◽  
Amanda Chang ◽  
Carol Gao ◽  
...  

HEXIM1 is often down-regulated in human triple-negative breast cancer (TNBC), and these cancer cells are highly sensitive to Hsp90 inhibitors. However, the mechanistic link between the two has not been determined. Our study provides a mechanistic explanation for the increased sensitivity of TNBC to Hsp90 inhibition.


2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Carlos Perez Kerkvliet ◽  
Amy Dwyer ◽  
Tarah Regan Anderson ◽  
Marissa Oram ◽  
Branden Smeester ◽  
...  

2013 ◽  
Vol 19 (22) ◽  
pp. 6163-6172 ◽  
Author(s):  
Maxwell N. Skor ◽  
Erin L. Wonder ◽  
Masha Kocherginsky ◽  
Anju Goyal ◽  
Ben A. Hall ◽  
...  

2017 ◽  
Vol 2017 ◽  
pp. 1-11 ◽  
Author(s):  
Wanqin Wang ◽  
Jun Zhao ◽  
Xiaoxia Wen ◽  
Curtis Chun-Jen Lin ◽  
Junjie Li ◽  
...  

AXL receptor tyrosine kinase is overexpressed in a number of solid tumor types including triple-negative breast cancer (TNBC). AXL is considered an important regulator of epithelial-to-mesenchymal transition (EMT) and a potential therapeutic target for TNBC. In this work, we used microPET/CT with 64Cu-labeled anti-human AXL antibody (64Cu-anti-hAXL) to noninvasively interrogate the degradation of AXL in vivo in response to 17-allylamino-17-demethoxygeldanamycin (17-AAG), a potent inhibitor of HSP90. 17-AAG treatment caused significant decline in AXL expression in orthotopic TNBC MDA-MB-231 tumors, inhibited EMT, and delayed tumor growth in vivo, resulting in significant reduction in tumor uptake of 64Cu-anti-hAXL as clearly visualized by microPET/CT. Our data indicate that 64Cu-anti-hAXL can be useful for monitoring anti-AXL therapies and for assessing inhibition of HSP90 molecular chaperone using AXL as a molecular surrogate.


Author(s):  
Julia Sperlich ◽  
Nicole Teusch

Pseudopterosin, produced by the sea whip of the genus Antillogorgia, possesses a variety of promising biological activities including potent anti-inflammatory effects. However, few studies examined pseudopterosin in the treatment of cancer cells and, to our knowledge, the ability to inhibit triple negative breast cancer (TNBC) proliferation or invasion has not been explored. Thus, we evaluated the as yet unknown mechanism of action of pseudopterosin: Pseudopterosin was able to inhibit proliferation of TNBC. Interestingly, analyzing breast cancer cell proliferation after knocking down glucocorticoid receptor α (GRα) revealed that anti-proliferative effects of pseudopterosin were significantly inhibited when GRα expression was reduced. Furthermore, pseudopterosin inhibited invasion of MDA-MB-231 3D tumor spheroids embedded in an extracellular-like matrix. Remarkably, the knockdown of GRα in 3D tumor spheroids revealed increased ability of cells to invade the surrounding matrix. In a co-culture, encompassing peripheral blood mononuclear cells (PBMC) and MDA-MB-231 cells, production of interleukin 6 (IL-6) and interleukin 8 (IL-8) significantly increased compared to monoculture. Notably, pseudopterosin proved to block cytokine elevation, representing key players in tumor progression, in the co-culture. Thus, our results reveal pseudopterosin treatment as a potential novel approach in TNBC therapy.


Sign in / Sign up

Export Citation Format

Share Document